Deuterated catecholamine derivatives and medicaments compromising said compounds

Abstract

The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically compatible salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders.

The invention claimed is: 
     
       1. Deuterated catecholamine derivatives of the general formula I 
       
         
           
           
               
               
           
         
         wherein R 1  is H or D, R2 indicates D, R 3  is H, D, C 1  to C 6 -alkyl or C 5  to C 6 -cycloalkyl, deuterated C 1  to C 6 -alkyl or deuterated C 5  to C 6 -cycloalkyl, R 4  indicates H or D and R 5  is H or hhD. 
       
     
     
       2. Deuterated catecholamine derivatives of the general formula I 
       
         
           
           
               
               
           
         
         wherein R 1  is H or D, R 2  indicates D, R 3  is D, C 1  to C 6 -alkyl or C 5  to C 6 -cycloalkyl, deuterated C 1  to C 6 -alkyl or deuterated C 5  to C 6 -cycloalkyl, R 4  indicates H or D and R 5  is H or D. 
       
     
     
       3. Deuterated catecholamine derivatives of the general formula I 
       
         
           
           
               
               
           
         
         wherein R 1  is H or D, R 2  indicates D, R 3  is H, D, C 1  to C 6 -alkyl or C 5  to C 6 -cycloalkyl, deuterated C 1  to C 6 -alkyl or deuterated C 5  to C 6 -cycloalkyl, R 4  indicates H or D and R 5  is H or D. 
       
     
     
       4. Deuterated catecholamine derivatives of the general formula I 
       
         
           
           
               
               
           
         
         wherein R 1  is H or D, R 2  indicates D, R 3  is C 1  to C 6 -alkyl or C 5  to C 6 -cycloalkyl, R 4  indicates H or D and R 5  is H or D. 
       
     
     
       5. Deuterated catecholamine derivatives of the general formula I 
       
         
           
           
               
               
           
         
         wherein R 1  is H or D, R 2  indicates D, R 3  is methyl, R 4  indicates H or D and R 5  is H or D. 
       
     
     
       6. Deuterated catecholamine derivatives of the general formula I 
       
         
           
           
               
               
           
         
       
       wherein R 1  is H or D, R 2  indicates D, R 3  is ethyl, R 4  indicates H or D and R 5  is H or D. 
     
     
       7. Deuterated catecholamine derivatives of the general formula I 
       
         
           
           
               
               
           
         
         wherein R 1  is H or D, R 2  indicates D, R 3  is perdeuteroethyl, R 4  indicates H or D and R 5  is H or D. 
       
     
     
       8. Deuterated catecholamine derivatives of the general formula I 
       
         
           
           
               
               
           
         
         wherein R 1  is H or D, R2 indicates D, R 3  is perdeuteroethyl, R 4  indicates H or D and R 5  is H or D. 
       
     
     
       9. Deuterated catecholamine derivatives of the general formula I 
       
         
           
           
               
               
           
         
         wherein R 1  is H or D, R 2  indicates D, R 3  is perdeuteroethyl, R 4  indicates D and R 5  is H or D. 
       
     
     
       10. A method for the treatment of treating a dopamine deficiency diseases or diseases disease, treating a disease which are is based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, or treating Parkinson's disease, treating restless leg syndrome, treating dystonia, for inhibiting prolactin secretion, for stimulating the release of growth hormone, for the treatment of treating neurological symptoms of chronic manganese intoxications intoxication, of treating amyotrophic lateral sclerosis and of, or treating multiple system atrophy, said method comprising administering to a patient in need thereof an effective amount of a compound of general formula I 
       
         
           
           
               
               
           
         
         wherein R 1  is H or D, R 2  indicates D, R 3  is H, D, C 1 -C 6 - alkyl or C 5  to C 6 -cycloalkyl, deuterated C 1  to C 6 -alkyl or C 5  to C 6 -cycloalkyl, R 4  indicates H or D and R 5  is H or D, and wherein the compound is selected from the group consisting of, 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)propionic acid;,  
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)methyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl) ethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)cyclohexyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuteromethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuteroethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuterocyclohexyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)propionic acid; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)methyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)ethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)cyclohexyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuteromethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuteroethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuterocyclohexyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dideuteroxyphenyl)perdeuterocyclohexyl propionate; and, 
       
       as well as or a physiologically compatible salts salt thereof. 
     
     
       11. The method of  claim 10 , wherein the compound as well as L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)propionic acid or the physiologically compatible salts salt thereof is administered in combination with an enzyme inhibitor or several enzyme inhibitors. 
     
     
       12. The method as claimed in of  claim 11 , wherein the enzyme inhibitor or the several enzyme inhibitors involve are decarboxylase inhibitors and/or catechol-O-methyltransferase inhibitors and/or monoamine oxidase inhibitors and/or β-hydroxylase inhibitors. 
     
     
       13. The method as claimed in of  claim 12 , wherein the decarboxylase inhibitor is selected from the group consisting of D,L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide (benserazide), (−)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid (carbidopa), L-serine 2-(2,3,4-trihydroxybenzyl)hydrazide, glycine 2-(2,3,4-trihydroxybenzyl) hydrazide and, or L-tyrosine 2-(2,3,4-trihydroxybenzyl)hydrazide as well as, or a physiologically compatible salts salt thereof. 
     
     
       14. The method as claimed in of  claim 12 , wherein the catechol-O-methyltransferase inhibitor is selected from entacapone and or cabergoline as well as or a physiologically compatible salts salt thereof. 
     
     
       15. The method as claimed in of  claim 12 , wherein the monoamine oxidase inhibitor is selected from the group consisting of selegiline, moclobemide and, or tranylcypromine as well as or a physiologically compatible salts salt thereof. 
     
     
       16. The method as claimed in of  claim 12 , wherein the β-hydroxylase inhibitor is selected from calcium 5-butyl picolinate and or calcium 5-pentyl picolinate as well as or a physiologically compatible salts salt thereof. 
     
     
       17. A method for the production of pharmaceuticals for treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, or Parkinson's disease, restless leg syndrome, dystonia, for inhibiting prolactin secretion, for stimulating the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple system atrophy, said method comprising the steps of providing a compound of general formula I 
       
         
           
           
               
               
           
         
         wherein R 1  is H or D, R 2  indicates D, R 3  is H, D, C 1 -C 6  alkyl or C 5  to C 6 -cycloalkyl, deuterated C 1  to C 6 -alkyl or C 5  to C 6 -cycloalkyl, R 4  indicates H or D and R 5  is H or D, and wherein the compound is selected from the group consisting of 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)propionic acid; 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)methyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl) ethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)cyclohexyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuteromethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuteroethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuterocyclohexyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)propionic acid; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)methyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)ethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)cyclohexyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuteromethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuteroethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuterocyclohexyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dideuteroxyphenyl)perdeuterocyclohexyl propionate; and 
       
       as well as physiologically compatible salts thereof and combining said compound and physiologically compatible salts with pharmaceutically compatible adjuvants and additives. 
     
     
       18. A pharmaceutical composition for the treatment of Parkinson's disease, of restless leg syndrome, of dystonia, for inhibiting prolactin secretion, for stimulating the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple system atrophy, which pharmaceutical composition comprises a compound of general formula I 
       
         
           
           
               
               
           
         
         wherein R 1  is H or D, R 2  indicates D, R 3  is H, D, C 1 -C 6  alkyl or C 5  to C 6 -cycloalkyl, deuterated C 1  to C 6 -alkyl or C 5  to C 6 -cycloalkyl, R 4  indicates H or D and R 5  is H or D, and wherein the compound is selected from the group consisting of comprising  
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)propionic acid; 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)methyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl) ethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)cyclohexyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuteromethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuteroethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl)perdeuterocyclohexyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)propionic acid; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)methyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)ethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)cyclohexyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuteromethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuteroethyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)perdeuterocyclohexyl propionate; 
         L-2-amino-2,3,3-trideutero-3-(2,3,6-trideutero-4,5-dideuteroxyphenyl)perdeuterocyclohexyl propionate; and 
       
       as well as or a physiologically compatible salts salt thereof, in addition to for treating Parkinson's disease, treating restless leg syndrome, treating dystonia, inhibiting prolactin secretion, stimulating the release of growth hormone, treating neurological symptoms of chronic manganese intoxication, treating amyotrophic lateral sclerosis, or treating multiple system atrophy, and a pharmaceutically compatible adjuvants and additives adjuvant or additive. 
     
     
       19. The pharmaceutical composition of  claim 18  further comprising one or more enzyme inhibitors. 
     
     
       20. The pharmaceutical composition according to  claim 19 , further characterized in that the enzyme inhibitor or the enzyme inhibitors involve decarboxylase inhibitors and/or catechol-O-methyltransferase inhibitors and/or monoamine oxidase inhibitors and/or β-hydroxylase inhibitors. 
     
     
       21. The pharmaceutical composition according to  claim 19 , further characterized in that the decarboxylase inhibitor is selected from the group consisting of D,L-serine 2-(2,3,4-trihydroxybenzyl)hydrazide(benserazide), (−)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid(carbidopa), L-serine 2-(2,3,4-trihydroxybenzyl)hydrazide, glycine 2-(2,3,4-trihydroxybenzyl)hydrazide and L-tyrosine 2-(2,3,4-trihydroxybenzyl)hydrazide as well as physiologically compatible salts thereof. 
     
     
       22. The pharmaceutical composition according to  claim 19 , further characterized in that the catechol-O-methyltransferase inhibitor is selected from entacapone and cabergoline as well as physiologically compatible salts thereof. 
     
     
       23. The pharmaceutical composition according to  claim 19 , further characterized in that the monoamine oxidase inhibitor is selected from the group consisting of selegiline, moclobemide and tranylcypromine as well as physiologically compatible salts thereof. 
     
     
       24. The pharmaceutical composition according to  claim 19 , further characterized in that the β-hydroxylase inhibitor is selected from calcium 5-butyl picolinate and calcium 5-pentyl picolinate as well as physiologically compatible salts thereof. 
     
     
       25. The method of claim 10 for treating Parkinson's disease.  
     
     
       26. The method of claim 10 for treating restless leg syndrome.  
     
     
       27. The method of claim 10 for treating dystonia.  
     
     
       28. The method of claim 10 for treating neurological symptoms of chronic manganese intoxication.  
     
     
       29. The method of claim 10 for treating amyotrophic lateral sclerosis.  
     
     
       30. The method of claim 10 for treating multiple system atrophy.  
     
     
       31. The pharmaceutical composition of claim 18, for treating Parkinson's disease.  
     
     
       32. The pharmaceutical composition as recited in claim 18, for treating restless leg syndrome.  
     
     
       33. The pharmaceutical composition of claim 18, for treating dystonia.  
     
     
       34. The pharmaceutical composition of claim 18, for treating neurological symptoms of chronic manganese intoxication.  
     
     
       35. The pharmaceutical composition of claim 18, for treating amyotrophic lateral sclerosis.  
     
     
       36. The pharmaceutical composition of claim 18, for treating multiple system atrophy.